Corporate Banner
Satellite Banner
Food & Beverage Analysis
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rhenovia Pharma Secures Series B Funding

Published: Thursday, February 13, 2014
Last Updated: Thursday, February 13, 2014
Bookmark and Share
The company raises EUR 540,000 (USD 738,000) from historical shareholders to expand its staff.

Rhenovia Pharma has announced that it has raised EUR 540,000 (USD 738,000) from its historical shareholders in a second round of funding.

Founded in 2007, Rhenovia is the world leader in biosimulation of the central nervous system. The company uses its unique technology to create computer simulators that predict the effect of molecules both on healthy patients and others living with conditions such as Alzheimer's disease, Parkinson's disease, epilepsy and depression.

The simulators considerably reduce the need for animal testing. They have numerous applications in the pharmaceutical and agrifood industries and within civilian and military security (neurotoxicity).

In 2009, Rhenovia obtained initial funding from a pool of investors drawn from the Alsace Business Angels and the SODIV fund providing support to SMEs in the Alsace region of France.

The second-round funding of EUR 540,000 announced today came from historical investors. The funds provide a boost to Rhenovia's capital and the means for it to add to its team of staff, particularly in the areas of marketing and therapeutic applications.

“The unfailing support of our historical shareholders has helped us to become the world leader in biosimulation of the central nervous system and to sign our first contracts with industrial partners,” said Dr Serge Bischoff, co-founder and CEO of Rhenovia. “This second round of funding is key to building our business development.”

Third-round funding planned for 2014

Rhenovia plans to complete a third round of funding of EUR 2 million in 2014. This will be open to new investors, particularly family offices. To date the company has largely self-funded its growth. It now intends to step up development across the three key markets that it already services: pharmaceutical, agrifood and neurotoxicity. Each of these three sectors has strong growth potential.

By using Rhenovia's technology, the pharmaceutical industry can identify new drug candidates and shorten lead times for development, reducing the costs of R&D. The technology also helps in anticipating risk (of side effects or interactions with other molecules, for example). As a result, it can reduce the rate of clinical stage failure. The health care and financial stakes are therefore considerable.

In the field of agrifood, Rhenovia's simulators help in the study of how the properties of foodstuffs, neutraceuticals and food supplements affect the central nervous system, contributing to R&D in the sector and to the validation of alleged health benefits. Another challenge is to improve the prevention of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases.

Rhenovia's technology can also measure the effects of neurotoxic agents such as pesticides, nanoparticles, industrial emissions and chemical weapons. It may also help in the development of antidotes to poison gas, making it of key interest to stakeholders in civil and military protection.

Rhenovia now has client contracts in each of these three markets.

Rhenovia provides high-value added consultancy services based on the use of its computer simulators, the development of new, bespoke simulators and licensing for new technologies.

The funding raised in 2014 should enable a rapid increase in Rhenovia's rate of business development. The company has particular plans to supplement its service offering, structuring it to suit each of its target markets with the intention of capturing a significant share of the international market for biosimulation of the central nervous system.

This market is showing strong growth. According to Rhenovia, it is expected to be worth several tens of millions of euros in 2018.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
How To Keep Your Rice Arsenic-Free
Researchers at Queen’s University Belfast have made a breakthrough in discovering how to lower worrying levels of arsenic in rice that is eaten all over the world.
Pesticide Found in 70 Percent of Massachusetts’ Honey Samples
New Harvard University study says that the pesticide commonly found in honey samples is implicated in Colony Collapse Disorder.
Printed "Smart Cap" Detects Spoiled Food
It might not be long before consumers can just hit “print” to create an electronic circuit or wireless sensor in the comfort of their homes.
Red Wine Antioxidant May Provide New Cancer Therapy Options
Resveratrol and quercetin, two polyphenols that have been widely studied for their health properties, may soon become the basis of an important new advance in cancer treatment,
New Research will Show How the Environment Could Change the Way We Eat
A new study funded by the Wellcome Trust will investigate how environmental changes over the next 20-30 years may impact the way we eat, in the UK and worldwide.
Blue LEDs Can be Used to Preserve Food
Blue light emitting diodes (LEDs) have strong antibacterial effect on major foodborne pathogens and can be used as a chemical-free food preservation method, a new study has found.
FDA Declares Trans Fatty Acids Unsafe for Consumption
TFAs are widely recognized as the most harmful fat with regard to causing cardiovascular disease (CVD).
Fat, Sugar Cause Bacterial Changes that may Relate to Loss of Cognitive Function
A study has indicated that both a high-fat and a high-sugar diet, compared to a normal diet, cause changes in gut bacteria that appear related to a significant loss of "cognitive flexibility," or the power to adapt and adjust to changing situations.
How Anthrax Spores Grow in Cultured Human Tissues
New findings to help predict risk and outcomes of anthrax attacks.
Food Research at the Microscale
Thermal stage microscopy allows food science microscopists to analyze samples under a range of conditions.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!